Nurix Therapeutics, Inc. (NRIX) Research

Nurix Therapeutics, Inc., a biopharmaceutical firm headquartered in San Francisco, California, was founded in 2009. This company, which rebranded from Nurix Inc. in October 2018, is dedicated to the identification, advancement, and commercialization of innovative small molecule treatments for various cancers and immune system disorders. Its robust pipeline features several key drug candidates: NX-2127 and NX-5948: Both are orally administered Bruton's tyrosine kinase (BTK) degraders, targeting B-cell malignancies that have relapsed or are resistant to prior therapies. NX-5948 is also being explored for autoimmune conditions. NX-1607: An orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, developed for immuno-oncology applications. NX-0255: A CBL-B inhibitor designed for ex vivo use to enhance the efficacy of adoptive T-cell therapies. DeTIL-0255: Currently undergoing Phase 1 clinical trials for gynecological cancers, including ovarian, endometrial, and cervical cancers. To further its mission, Nurix has forged significant strategic alliances, notably with Gilead Sciences, Inc. for the development of therapies addressing cancer and other challenging diseases, and also with Sanofi S.A.

Market snapshot

Symbol
NRIX
Price
$17.55
Day change
+2.51%
Market cap
$1.5B
P/E ratio
-6.54x
52-week range
8.195-22.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 20 days
Analyst price target
$33.00

Recent news

  • This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

    Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.

  • Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying

    Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg.

  • Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

    Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock is up during Monday's premarket session as the company collaborates with Roche Holdings AG (OTC:RHHBY) to co-develop and co-commercialize bexobrutideg, an investigational Bruton's Tyrosine Kinase (BTK) degrader.

Peer companies

  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Fortrea Holdings Inc. (FTRE)
  • Kodiak Sciences Inc. (KOD)
  • Kura Oncology, Inc. (KURA)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • Septerna, Inc. (SEPN)
  • Tango Therapeutics, Inc. (TNGX)

Recent insider activity

  • Ring Christine — M-Exempt (3422 shares) on 2026-06-02
  • Ring Christine — S-Sale (8148 shares) on 2026-06-02
  • Ring Christine — M-Exempt (3422 shares) on 2026-06-02
  • Silva Paul M — A-Award (31250 shares) on 2026-05-15
  • Saltzman Edward C — A-Award (31250 shares) on 2026-05-15

Open Nurix Therapeutics, Inc. (NRIX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.